AbbVie Exercises Exclusive Option to License Argenx’s ARGX-115

 AbbVie Exercises Exclusive Option to License Argenx’s ARGX-115

AbbVie Exercises Exclusive Option to License Argenx’s ARGX-115

Shots:
  • AbbVie will obtain a worldwide, exclusive license to develop and commercialize ARGX-115-based products
  •  Argenx to receive development, regulatory and commercial milestone payments of up to $625M, and has rights to co-promote ARGX-115 products in the EU and Swiss Economic Area
  • Argenx and AbbVie previously entered into an option and license agreement for ARGX-115 in April 2016, for development and commercialization of ARGX-115

Click here to read full press release/ article | Ref: Argenx | Image:  Cantilis

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post